The endometriosis treatment market across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is projected to grow at a CAGR of 10.3%, rising from $938 million in 2024 to $2.5 billion by 2034, according to GlobalData’s latest report, Endometriosis: Seven Market Drug Forecast and Market Analysis.

This robust growth is attributed to the expected launch of innovative therapies such as Kissei Pharmaceutical’s Yselty (linzagolix), a GnRH antagonist already available in Europe and soon launching in the US and Japan. Hope Medicine’s HMI-115, a prolactin receptor antagonist, and Fuji Pharma’s Alyssa (drospirenone + estetrol) are also anticipated to contribute significantly to market expansion.

Increased disease awareness, improved diagnostic tools—especially biomarker-based non-invasive tests—and earlier detection are boosting diagnosis rates. Among the pipeline therapies, Yselty is expected to lead with forecasted sales of $664.5 million by 2034.

Dr. Shireen Mohammad, Senior Analyst at GlobalData, noted that key unmet needs include non-invasive diagnostics, improved physician education, more effective and tolerable treatments, non-hormonal therapy options, and deeper understanding of disease etiology. Current hormonal treatments induce a temporary menopausal state, limiting fertility and causing hypoestrogenic side effects. The need for non-hormonal treatments is especially critical for women of reproductive age and adolescents.

HMI-115 represents a promising non-hormonal approach, addressing the fertility concerns associated with hormonal therapies. However, the widespread use and low cost of hormonal contraceptives may pose a challenge to market uptake of new therapies.

Despite this, GlobalData forecasts strong growth, with next-generation drugs poised to reshape the treatment landscape for this estrogen-dependent and often underdiagnosed condition.